Rylan H.

Rylan H. is an accomplished regulatory professional currently serving as Executive Director of Regulatory Strategy at Neurocrine Biosciences, focusing on global regulatory leadership for the marketing of INGREZZA. Prior to this role, Rylan held senior regulatory positions at Intercept Pharmaceuticals and Amgen, where substantial expertise in managing regulatory activities for marketed products and leading global regulatory strategies was developed. Rylan's past experience includes serving as a Legal and Regulatory Analyst at the FDA, where a strong foundation in regulatory policies and practices was established. Rylan holds a Pharm.D. from the University of Southern California and a B.S. in Biology from California State University-San Bernardino.